HERG Screening Market Share, Size, Analysis Report, 2024-2032
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
The global HERG screening market was valued at USD 2,082.76 million in 2023 and is expected to grow at a CAGR of 12.7% during the forecast period.
hERG stands for human Ether-a-go-go-Related Growth. Gene has made advantage of his contribution to cardiac activity. Its channels assist the heart beat by moderating repolarizing current in the cardiac action potential. It encodes the protein Kv11.1, which functions as the alpha subunit of a potassium ion channel. Before the filing of an experimental new medication, regulatory authorities have made hERG evaluations a priority requirement. Manual/automatic patch-clamp test, hERG radioligand binding assay, fluorescence polarization assay, and microelectrode array are some of the hERG screening assays.
To Understand More About this Research: Download Sample Report
The HERG screening market is being driven by the increasing number of innovative medication approvals and the rising prevalence of cardiac disorders. However, the high cost of hERG screening tools is projected to stifle market growth throughout the projection period. Nonetheless, unexplored markets are anticipated to create a lucrative potential for this market's growth in the near future.
The primary application of hERG screening is in the drug discovery process. In the next years, the rising number of product releases is expected to drive up demand for hERG screening. The rising number of innovative medication approvals is projected to promote the drug discovery process, which will aid in the growth of the market.
The automated patch-clamp test measures hERG current at various doses. It is carried out both before and after exposure to test chemicals. The IC50 values are then established using a procedure known as dosage formulation analysis. Similarly, the other tests are carried out in accordance with their respective standards. hERG screening provides several advantages, including the existence of a channel that serves as a target for class III antiarrhythmic medicines such as amiodarone. It increases the action potential while decreasing the danger of re-entrant arrhythmias. It can be utilized as a diagnostic marker in the treatment of disorders such as cancer, recurring epileptic seizures, and schizophrenia.
For Specific Research Requirements, Request for a Customized Research Report
Growth Drivers
- Increasing prevalence of cardiovascular disease
The growing acceptance of innovative medications and the increasing prevalence of heart diseases are driving the global market. In any event, unknown company areas are likely to provide a profitable opportunity for the market's development in the near future. HERG screening is mostly used for medication disclosure purposes. The growing number of item deliveries is expected to fuel demand in hERG screening in the future years. According to the Center for Drug Evaluation and Research (CDER) annual report, an estimated 25 drugs received new medication endorsement for promotion in 2016, while only 59 did so in 2018. The increasing number of new drug endorsements is required to aid the medication disclosure measure that aids the development of the hERG screening company sector.
Report Segmentation
The market is primarily segmented based on product type, ion channel, application, and region.
| By Product Type | By Ion Channel | By Application | By Region |
|
|
|
|
To Understand the Scope of this Report: Request Customization
By Product Type Analysis
KCNH2 gene segment accounted for the largest revenue share over the study period. KCNH2 gene is part of a wide family of genes that code for potassium channel instructions. These channels, which carry positively charged potassium atoms (ions) out of cells, are critical to a cell's capacity to create and send electrical impulses. A potassium channel's unique function is determined by its protein components and location in the body. Channels consisting of KCNH2 proteins function in heart muscle. They are responsible for re-charging the cardiac muscle after each beating in order to keep the rhythm consistent. In the brain and spinal cord, KCNH2 protein is also generated by nerve cells and some immune cells (microglia) (central nervous system).
A KCNH2 mutation causes the cardiac arrhythmia. Also, long QT syndrome is caused by the mutation in KCNH2 gene, and an estimated 1 in 5,000 to 10,000 persons worldwide suffer from the long QT syndrome. Some of these mutations alter single protein building blocks in the protein, while others remove several amino acids. These modifications either prohibit the protein from gathering into ion channels or to modify the function of the channels. As a result, the channels are unable to control the flow of potassium ions in heart muscle cells adequately. Reduced ion transport changes electrical signal transmission in the heart, increasing the likelihood of an irregular heartbeat, which can result in fainting.
By Ion Channel Analysis
In 2023, Voltage gated ion channels dominated the market. They comprise another huge group, with each member having a distinct ion selectivity and voltage dependency. Many are also time-dependent, which means they do not respond to a voltage change instantly, but rather after a delay. Voltage-gated channels are required for action potential generation and propagation.
Over the projection period ligand gated channel expected to register the highest growth. Ligand-gated ion channels are the gated channels whose permeability increases dramatically when a chemical ligand attaches to the protein structure. The fastest-growing sector is ion gated channels. A vast subset operates as neuro-transmitter receptors, as they are found at postsynaptic locations and are activated by a chemical ligand produced by the pre-synaptic axons. Ligand channels are triggered by ligands that emerge in the extracellular space or by intracellular contacts.
By Application Analysis
The antiarrhythmic medication application sector is expected to account for a sizable market share. The growing need for medication modification ion channel activity for use in cardiovascular illnesses, metabolic disorders, and cancer is propelling the market forward. Amiodarone, a class III medication, inhibits HERG channels in both the closed and open states, and clinical evidence clearly suggest that it is a highly safe and effective antiarrhythmic medicine. It is likely that further therapy with -blocking medications, or intrinsic -blocking action of the medicines, is required to prevent proarrhythmias in a manner that is currently unclear. Similarly, the added HERG blocking action of amiodarone or carvedilol may result in greater clinical outcomes as compared to traditional treatment with pure -blocking drugs.
High levels of the macrolide antibiotics erythromycin and clarithromycin in the blood inhibit the IKr current and affect the cardiac repolarization process. Furthermore, they can inhibit CYP3A4, increasing the risk of using other torsadogenic drugs. Fluoroquinolonic antibiotics such as sparfloxacin and grepafloxacin can also cause QT prolongation and torsade de pointes. The use of high amounts of psychoactive drugs, either first or second generation, has been linked to changes in cardiac repolarization and instances of torsade de pointes.
Regional Insights
In 2023, North America accounted for the largest revenue share of the global market. This share can be contributed to technological advancement and the region’s high frequency of cardiac complaint. According to the American College of Cardiology, an estimated 356,461 Americans failed from out of sanitarium cardiac arrest in 2017, also, increased new medicine launches will prop request growth. According to the center for medicine evaluation and exploration periodic report, an estimated 25 medicines entered new medicine blessings for marketing in 2016, with 59, in 2018.
Asia Pacific is expected to experience the rapid growth in the market due to improved reimbursement well designed policies, healthcare infrastructure, and improving economic growth, all of which will have a great positive impact on the market. The market will benefit from increased initiatives by non-profit organizations in the region.
Key market players and Competitive Insight
The market is characterized by intense competition, with established players relying on advanced technology, high-quality products, and a strong brand image to drive revenue growth. These companies employ various strategies such as research and development, mergers and acquisitions, and technological innovations to expand their product portfolios and maintain a competitive edge in the market.
Some of the major players operating in the global market include
- Abcam PLC
- ABR-Affinity Bioreagents
- AstraZeneca
- Aureus Sciences
- Aurora Sciences
- AVIVA Biosciences
- B’SyS GmbH
- Caliper
- Cambridge Biosciences
- Cellular Dynamics
- ChanTest Corporation
- Charles River Laboratories
- ChemAxon
- Eurofins-Cerep SA
- Molecular Devices
- PerkinElmer Company
Recent Developments
- In July 2017, Eurofins Scientific announced the purchase of Discover X. From target identification and lead discovery through the preclinical stage and beyond, this is a key agent in drug discovery goods and services.
- In March 2020, Charles River Laboratories will collaborate with Deciphex. They are currently collaborating to create deep learning-enabled solutions to aid with rapid pathology analyses.
HERG Screening Market Report Scope
| Report Attributes | Details |
| Market size value in 2024 | USD 2,343.11 million |
| Revenue forecast in 2032 | USD 6,108.75 million |
| CAGR | 12.7% from 2024 - 2032 |
| Base year | 2023 |
| Historical data | 2019 - 2022 |
| Forecast period | 2024 - 2032 |
| Quantitative units | Revenue in USD million and CAGR from 2024 to 2032 |
| Segments covered | By Product Type, By Ion Channel, By Application, By Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
| Customization | Report customization as per your requirements with respect to countries, region and segmentation |
FAQ's
key companies in HERG screening market are Abcam PLC, PerkinElmer Company, ABR-Affinity Bioreagents, AstraZeneca, Aureus Sciences, Aurora Sciences
The global HERG screening market is expected to grow at a CAGR of 12.7% during the forecast period.
The HERG screening market report covering key segments are product type, ion channel, application, and region.
key driving factors in HERG screening market are Increasing Drug Discovery and Development
The global HERG screening market size is expected to reach USD 6.10 billion by 2032
Research Methodology
A robust system of research, verification, and forecasting designed to ensure reliable and actionable market insights.
Polaris Market Research & Consulting, Inc. uses a clear and structured approach to deliver insights that clients can rely on. The process combines detailed primary and secondary research, including direct communication with industry experts. The detailed information helps build a complete picture of market trends and developments. Secondary data is gathered from credible sources such as industry reports, company filings, government source links, and trusted organization databases. It is then cross-checked through discussions with key stakeholders across the value chain. Market size and forecasts are developed using both bottom-up and top-down methods to ensure accuracy and consistency in the final results.
1. Project Setup
Step 1 & 2:
- We start every project by clearly understanding the client’s objective or goal, then defining the market scope, and aligning regions, segments, and timelines.
- Once the foundation is set, we collect data from all-around of sources, including company reports, government databases, and paid industry platforms.
- Our research is based on secondary data, which helps us build a strong understanding of the market across regions and industries. Then we validate this information through primary research by speaking directly with industry experts, companies, and stakeholders.
- By combining secondary and primary research, we ensure that our market insights are accurate, practical, and closely aligned with real market conditions.
2. Data Collection
We gather information from both public and verified sources:
3. Data Structuring
Step 3:
- All collected data is organized into a consistent format to ensure accurate analysis. Since inputs come from multiple sources, they are standardized and aligned before use.
- The data is segmented by product, application, and region, and mapped across a defined historical period (2020–2024). All values are converted into common units (USD Mn/Bn), and volume and pricing are aligned where required to estimate revenue.
- Any overlaps or inconsistencies are reviewed and adjusted to maintain accuracy (<5% variance threshold).
- The result is a structured dataset that allows for clear comparison across regions and supports reliable analysis and forecasting.
Structured Market Dataset, USD Mn/Bn
| Region | Segment | VolumeUnits | Avg PriceUSD | RevenueUSD Mn | Share % |
|---|---|---|---|---|---|
| North America | Product A | 250 | 2.5 | 500 | 15% |
| Product A | XX | XX | XX | XX | |
| Product A | XX | XX | XX | XX | |
| Consistent methodology applied across regions | |||||
4. Market Estimation
Step 4: TOP-DOWN APPROACH
- We start with the overall market size at a global or macro level.
- The market is then narrowed down based on scope and industry relevance.
- We apply penetration rates and split the data by region and segment.
- This helps us estimate the market size for specific segments.
- The numbers are validated through cross-checks to ensure accuracy.
Step 5: BOTTOM-UP APPROACH
- We begin by analyzing data from leading companies in the market.
- Revenue data is collected and mapped across different segments.
- The data is then aggregated to estimate the total market size.
- To fill in any gaps, adjustments are made based on industry standards.
- Validation checks make sure that the results are correct.
5. Forecasting
Step 6:
At Polaris Market Research & Consulting, Inc., we employ a methodical forecasting strategy. This approach blends the analysis of historical data with real-time market validation. To forecast future trends with precision, we examine past patterns, pricing fluctuations, and the interplay of supply and demand. To ensure our conclusions reflect the present market landscape, we actively seek input from industry experts and key stakeholders.
To refine our predictions, we carefully consider critical elements such as market drivers and restraints, fluctuations in raw material costs, emerging technologies, and the production capabilities of various regions. Furthermore, we assess regulatory frameworks and potential policy shifts to gauge their potential impact on market expansion.
All this information is synthesized to generate precise forecasts for each segment and region. These forecasts illuminate the current state of the market and highlight forthcoming opportunities.
6. Validation & Triangulation
Step 7:
In the final stage, we validate all our estimates using a triangulation method, where data is cross-checked from multiple reliable sources, like company data, primary interviews, and secondary research. This helps us make sure that our numbers are correct and fit with the rest of the market.
This process involves verifying data consistency across various segments and geographic areas. It also requires comparing historical trends with the assumptions support the forecast. Any discrepancies involve adjustments to ensure everything remains aligned and dependable.
Once the data is finalized, we prepare the final outputs, including market size estimates, segment-wise breakdowns, and growth metrics. These are delivered in structured formats such as tables, charts, and data files for easy analysis and use.
We collaborate closely with clients, ensuring the final products align with their requirements. This includes offering tailored adjustments, supplementary data analyses, and continuous assistance. Furthermore, we monitor market trends post-delivery, providing updates and refinements to maintain the insights' relevance as time passes.
Triangulation Framework
Estimates are cross-verified across three sources:
Company-level data
• Primary inputs from industry participants
• Secondary benchmarks and published data
Variance maintained within +5-10%
Adjustments applied to align estimates
Segment values validated against overall market structure
Data Consistency & Integrity
Segment totals validated to 100%
Regional estimates aligned with global market size
Historical trends compared against forecast outputs
Assumptions reviewed for cross-segment and regional alignment
Final Outputs
Deliverables
Client Alignment & Support
- Deliverables are aligned with defined client requirements and scope
- Custom data cuts and segment splits are incorporated as required
- Post-delivery queries are addressed through analyst interactions
- Additional clarifications and data support are provided upon request
Client Continuity & Updates
- Market developments are tracked post-delivery to capture changes in key trends
- Updated data and revisions are provided based on new market inputs
- Additional refinements and data cuts are shared as required
- Continued analyst engagement supports evolving client requirements
Download Sample Report of HERG Screening Market
Please fill out the form to request a customized copy of the research report.
